Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer
Agnes Stachnik(Icahn School of Medicine at Mount Sinai), Mone Zaidi(Icahn School of Medicine at Mount Sinai), Sudeh Izadmehr(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Shiraz Mujtaba(City University of New York), Tony Yuen(Icahn School of Medicine at Mount Sinai), Christoph Buettner(Icahn School of Medicine at Mount Sinai), Shozeb Haider(University College London), Jaya Sangodkar(Pediatrics and Genetics), Thomas Scherer(Medical University of Vienna), Goutham Narla(Pediatrics and Genetics), Graziana Colaianni(University of Bari Aldo Moro), Yogesh K. Gupta(The University of Texas at San Antonio Health Science Center), Yaoting Ji(Wuhan University), Zhuan Bian(Wuhan University), Jameel Iqbal(DaVita Clinical Research (United States)), Aneel K. Aggarwal(Icahn School of Medicine at Mount Sinai), Se‐Min Kim(Icahn School of Medicine at Mount Sinai), Alberta Zallone(University of Bari Aldo Moro), Peng Liu(Shenyang Pharmaceutical University), Jianhua Li(Guangdong Medical College), Ling-Ling Zhu(Icahn School of Medicine at Mount Sinai), Ping Lü(Cornerstone University), Maria I. New(Unknown), Li Sun(Wuhan University), Miriam Sgobba(University College London), Solomon Epstein, Jorge Gómez(Icahn School of Medicine at Mount Sinai)
Cited by 55
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k